ReviewRenal failure2025
Pyroptosis-induced tissue damage in kidney disease.
Review in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The gasdermin family: from pyroptosis mechanisms to therapeutic targets.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pyroptosis is a form of programmed cell death that differs mechanistically from apoptosis and is characterized by a robust inflammatory response. It is primarily mediated by proteins of the gasdermin family, which form pores in the cell membrane, leading to osmotic cell lysis and the release of pro-inflammatory cytokines. As a process triggered by various pathological stimuli like infection, inflammation, and oxidative stress, pyroptosis contributes to a range of diseases, including autoimmune disorders and cancer. Evidence indicates that pyroptosis, a crucial innate immune component, promotes host defense by facilitating immune cell recruitment and tissue repair. However, dysregulated pyroptosis is a key driver of pathology, contributing to chronic inflammation, fibrosis, and tissue damage in a range of conditions such as kidney, cardiovascular, and metabolic disorders. More evidence suggests that pyroptosis may dominate the process of irreversible damage to renal tissue and may accelerate the time for patients to enter end-stage renal disease. At present, when diagnosing kidney diseases and performing kidney biopsy, more attention is paid to the extent of kidney tissue damage, which is strongly related to the prognosis of patients. Given that many kidney diseases, especially acute kidney injury, involve inflammatory responses, targeting dysregulated pyroptosis presents a potential strategy for alleviating irreversible renal damage. This review will provide a detailed description of the signaling pathways of pyroptosis, with a focus on the mechanisms of pyroptosis-induced renal tissue damage and new advances in treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.